New Delhi, Mar 31 (PTI) Drug firm Lupin on Monday said its board has approved the transfer of its API R&D division to a wholly owned subsidiary on a slump sale basis.

The company's board has also approved modification to an earlier slump sale transaction by including an additional brand as part of the transfer of OTC business to LCHL, on a going concern basis, the drug maker said in a regulatory filing.

Also Read | What Is NITI NCAER States Economic Forum Portal To Be Launched by Nirmala Sitharaman on April 1?.

The company had intimated on February 12 this year regarding the board's approval for the transfer of the OTC Consumer Healthcare Business to a new wholly owned subsidiary.

The company has incorporated LUPINLIFE Consumer Healthcare Ltd, a wholly owned subsidiary for the purpose.

Also Read | Bank Holidays in April 2025: Banks To Remain Closed for 10 Days This Month, Check Complete List of Bank Holiday Dates.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)